Walking Fish Therapeutics Raises $73M in Series A Financing

Walking Fish Therapeutics

Walking Fish Therapeutics, a South San Francisco, Calif.-based leader in B cell therapeutics, closed a $73m Series A financing.

The round was co-led by Northpond Ventures and First Spark Ventures, with participation from Terra Magnum Capital Partners. Daniel Janse, Ph.D. from Northpond Ventures and Manish Kothari, Ph.D. from First Spark Ventures will be joining the board of directors.

The company intends to use the funds to advance a pipeline of B cell therapeutics for oncology, rare disease, regenerative medicine, autoimmune disease, and recombinant antibody production.

Led by Co-Founder and CEO, Dr. Lewis “Rusty” Williams, Walking Fish Therapeutics made its debut in September 2021 with the launch of Series A financing led by Emerson Collective, Illumina Ventures, and Quan Capital. Since the launch of Series A financing in September, the company’s platform for protein factories and oncology applications has continued to demonstrate positive preclinical data across multiple indications.